Novo's Awiqli® receives FDA approval as the first and only once-weekly insulin for children 10 years of age and older with type 2 diabetes

Awiqli® offers children 10 years and older a once-weekly basal insulin alternative, reducing basal injection frequency from seven times per week to one1 As type 2 diabetes incidence rates among youth continue to rise,² Awiqli® may help reduce administration barriers associated with daily...

Read the full story at Novo Nordisk via PR Newswire (opens in a new tab)

Headline and summary from Novo Nordisk via PR Newswire; the full story is on the publisher's site. Nothing here is investment advice.